Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211510 · ClinicalTrials.gov registry record · NA
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 146
- Enrollment target
NCT00211510: Completed NA study, sponsored by Medtronic MiniMed.
NCT00211510 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211510, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.
Interventions
- DEVICE Paradigm 722 sensor augmented pump
- DEVICE Paradigm 715 insulin pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211510
The ClinicalTrials.gov registry entry for NCT00211510 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic MiniMed, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paradigm 722 sensor augmented pump is the first listed.
NCT00211510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211510 about?
NCT00211510 is a clinical study titled "Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes". The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.
What is the current status of trial NCT00211510?
This trial is currently completed. It is a NA study. The enrollment target is 146 participants. The study started on 2005-06. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00211510?
The interventions under investigation include: Paradigm 722 sensor augmented pump (DEVICE), Paradigm 715 insulin pump (DEVICE).
Who is sponsoring clinical trial NCT00211510?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.